The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling via the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2+ breast cancer. We investigated the effec...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chaokun Wang, Shuzhen Deng, Jing Chen, Xiangyun Xu, Xiaochen Hu, Dejiu Kong, Gaofeng Liang, Xiang Yuan, Yuanpei Li, Xinshuai Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-05-01
Colecção:	Frontiers in Oncology
Assuntos:	HER2 positive breast neoplasm pyrotinib adriamycin synergistic Akt
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.616443/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!